Form 4: Regulus Therapeutics Director Disposes of Shares and Options Following Novartis Acquisition

A recent SEC Form 4 filing reveals that Hugh Rosen, a Director at Regulus Therapeutics Inc., has disposed of all his common stock, restricted stock units, and stock options as a result of the company's acquisition by Novartis AG.

Summary

• Regulus Therapeutics Inc. has been acquired by Novartis AG through its wholly-owned indirect subsidiary, Redwood Merger Sub Inc., effective June 25, 2025.
• The acquisition was executed via a cash tender offer, where each share of Regulus Therapeutics common stock was exchanged for an 'Offer Price'.
• The 'Offer Price' consists of $7.00 in cash per share (the 'Closing Amount') plus one Contingent Value Right (CVR) per share.
• Each CVR represents the right to receive an additional contingent payment of $7.00 in cash upon the achievement of a specified milestone.
• Director Hugh Rosen disposed of 6,979 shares of common stock and 57,292 shares of common stock (linked to restricted stock units) as part of this merger.
• All outstanding and unexercised stock options held by Mr. Rosen were also canceled and converted into cash payments and/or CVRs based on their exercise price relative to the Closing Amount.
• In-the-Money Options (exercise price less than $7.00) were converted into cash equal to the Closing Amount minus the exercise price, plus one CVR per share.
• Out-of-the-Money Options (exercise price equal to or greater than $7.00 but less than $14.00) were converted into one CVR per share, with a potential cash payment if the CVR milestone is met.
• Following these transactions, Hugh Rosen beneficially owns 0 shares of common stock and 0 derivative securities of Regulus Therapeutics Inc.

Sentiment

Score: 7

Explanation: The sentiment is generally positive as the merger provides a premium cash payment and potential upside via a CVR for shareholders, representing a successful exit for the company. The contingency of the CVR introduces some uncertainty, preventing a perfect score.

Positives

• The acquisition provides Regulus Therapeutics shareholders with immediate cash value of $7.00 per share.
• Shareholders also receive a Contingent Value Right (CVR) which offers potential for an additional $7.00 per share, providing upside potential based on future milestones.
• The transaction provides a clear exit strategy and liquidity for Regulus Therapeutics shareholders.

Negatives

• Regulus Therapeutics Inc. ceases to be an independent publicly traded company, becoming a wholly-owned subsidiary of Novartis AG.
• The full value of the CVR ($7.00) is contingent upon the achievement of a specific milestone, meaning the total potential payment of $14.00 per share is not guaranteed.
• Stock options with an exercise price equal to or greater than $14.00 would not receive any payment, though none of the reported options fell into this category.

Risks

• The primary risk is that the milestone specified in the CVR Agreement may not be achieved, in which case the contingent payment of $7.00 per CVR will not be made.
• The value of the CVR is entirely dependent on the future performance and strategic decisions of Novartis AG regarding the underlying asset or milestone.

Future Outlook

Regulus Therapeutics Inc. is now a wholly-owned subsidiary of Novartis AG. Its future operations and strategic direction will be determined by Novartis. The potential for the contingent value right (CVR) payment depends on the achievement of a specific milestone, which will dictate the final value received by former Regulus shareholders.

Industry Context

This transaction reflects a continuing trend of consolidation within the biotechnology and pharmaceutical sectors, where larger companies acquire smaller, innovative firms to expand their pipelines or gain access to specific technologies. The use of Contingent Value Rights (CVRs) in M&A deals is a common mechanism to bridge valuation gaps and share future risks/rewards, particularly in biotech where asset value is often tied to clinical development milestones.

Stakeholder Impact

• Shareholders: Received $7.00 cash per share and one CVR per share, providing immediate liquidity and potential future upside.
• Employees (with equity): Their restricted stock units and stock options were converted into cash and/or CVRs, aligning their interests with the merger outcome.
• Company (Regulus Therapeutics Inc.): Ceases to be an independent entity and operates as a wholly-owned subsidiary of Novartis AG.

Next Steps

• Monitoring the progress towards the milestone specified in the CVR Agreement to determine if the contingent payment of $7.00 per CVR will be made.

Key Dates

Keywords

Regulus Therapeutics, Novartis AG, Merger, Acquisition, SEC Form 4, Insider Transaction, Contingent Value Right, CVR, Stock Options, Beneficial Ownership, Biotechnology, Pharmaceuticals